Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis

The growing pipeline of therapeutics designed for subcutaneous delivery, coupled to the rising preference for self-medication, is expected to present lucrative opportunities for subcutaneous formulation technology and drug delivery device developers

This image opens in the lightbox

News provided by

Roots Analysis

26 May, 2020, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, May 26, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" report to its list of offerings.

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link

Key Market Insights

More than 180 organizations claim to be engaged in the development of subcutaneous biologics
The market is characterized by the presence of over 100 approved biologics, while more than 350 such drug candidates are presently being evaluated across different clinical stages. Of the total number of such drugs, over 115 are intended for treating autoimmune disorders, followed by metabolic disorders (65+) and oncological disorders (60+).

300+ subcutaneous drug delivery systems are presently available / under development
More than 100 of these subcutaneous drug delivery systems are large volume wearable injectors and autoinjectors. In addition, we identified around 80 pen-injectors and close to 40 needle free injectors that are designed to facilitate subcutaneous drug delivery.

Over 90% of subcutaneous formulation technology developers are small or mid-sized players Further, more than 60% of such companies are based in North America; key hubs in the region include (in decreasing order of number of companies) Massachusetts, California and New Jersey. It is also worth noting that most of the available technology platforms (over 70%) are either focused on facilitating the delivery of highly concentrated / viscous protein formulations, or enabling extended / controlled / sustained delivery of biologics.

Several partnerships have been inked by subcutaneous formulation technology developers since 2011
The report covers over 50 deals, most of which (18) were signed in 2018 and 2019. It is worth highlighting that around 40% of the total partnerships were technology licensing agreements, followed by deals related to formulation development (30%).

By 2030, revenues from sales of self-medication enabling devices are estimated to reach USD 10 billion
Currently, prefilled syringes are estimated to be responsible for the dominant share (over 40%) of revenues generated in this market. However, in the foreseen future, the contributions of other drug delivery devices, such as large volume wearable injectors (for non-insulin biologics) and autoinjectors, are expected to grow at a relatively faster pace (CAGR ~40% and ~10%, respectively).

Moreover, ~80% of revenues of subcutaneous technology developers are estimated to be generated through milestone payments
As the demand for subcutaneous drug formulations continues to increase, more licensing agreements between drug and technology developers are likely to be inked. From the technology licensing perspective, the opportunity is anticipated to grow at a CAGR of over 15% during the forecast period (2020-2030).

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • Who are the leading drug developers engaged in the development of subcutaneous biologics?
  • Who are the leading subcutaneous drug delivery device developers?
  • How many subcutaneous biologics are presently marketed / under clinical evaluation?
  • What are the popular technologies / platforms being used for the development and formulation of subcutaneous biologics?
  • What kind of partnership models are commonly adopted by stakeholders in this industry?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

  • Phase of development
    • Approved
    • Pre-registration & Phase III
    • Phase II & Phase II/III
  • Type of molecule
    • Cell and gene therapies
    • Monoclonal antibodies
    • Proteins
    • Peptides (recombinant)
    • Vaccines
    • Others
  • Target therapeutic area
    • Autoimmune disorders
    • Blood disorders
    • Bone disorders
    • Genetic disorders
    • Metabolic disorders
    • Neurological disorders
    • Oncological disorders
    • Respiratory disorders
    • Others
  • Type of drug delivery system
    • Large volume wearable injectors
    • Autoinjectors
    • Prefilled syringes
    • Needle-free injectors
    • Drug reconstitution systems
  • Revenues from licensing deals
    • Upfront payments
    • Milestone payments
  • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, a significant increase in demand for subcutaneous biologics and affiliated drug delivery systems is likely to be observed in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:

  • Deborah Bitterfield (Founder and Chief Executive Officer, Lindy Biosciences)
  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Steve Prestrelski (Founder and Chief Scientific Officer, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Senior Scientist, Formulation, Xeris Pharmaceuticals)
  • David Daily (Co-Founder and Chief Executive Officer, DALI Medical Devices)
  • Michael Reilly (Co-Founder and Chief Executive Officer and Co-Founder, Excelse Bio)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
  • David Heuzé (Communication Leader, MedinCell)

The research covers detailed profiles of key players (listed below); each profile features overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.

  • Adocia
  • Ajinomoto Bio-Pharma Services
  • Arecor
  • Alteogen
  • Ascendis Pharma
  • Avadel Pharmaceuticals
  • Camurus
  • Creative BioMart
  • Creative Biolabs
  • DURECT
  • Eagle Pharmaceuticals
  • Halozyme Therapeutics
  • MedinCell
  • Xeris Pharmaceuticals
  • Serina Therapeutics

For additional details, please visit 

https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html or email sales@rootsanalysis.com 

You may also be interested in the following titles:

  1. Global Autoinjectors Market (3rd Edition), 2020-2030
  2. Prefilled Syringes Market (5th Edition), 2020-2030
  3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030
  4. Large Volume Wearable Injectors Market (4th Edition), 2018-2030

Contact:
Gaurav Chaudhary
+1-(415)-800-3415
+44-(122)-391-1091
Gaurav.Chaudhary@rootsanalysis.com

LOGO: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.